EANS-Adhoc: NiteWatch Home Sleep Testing service receives Joint Commission accreditation as an "Ambulatory Health Care Program"

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

New Products/NiteWatch Accreditation

23.11.2009

Neuhausen am Rheinfall / Switzerland, November 23, 2009 - LifeWatch
AG (SIX Swiss Exchange: LIFE), the leading provider of wireless
cardiac and other medical monitoring services in the U.S., announced
today that its "NiteWatch" home sleep testing service has been
accredited with the Joint Commission for "Ambulatory Health Care
Programs", and is one of only a few independent diagnostic testing
facilities (IDTFs) which have received this Gold Seal of Approval.

"Joint Commission certification endorses LifeWatch as an organization
committed to clinical excellence and quality" stated Marikay Menard,
Vice President of Clinical Strategy and Regulatory Affairs of
LifeWatch Services, Inc. "The expansion of this certification to our
NiteWatch Home Sleep Testing service confirms this commitment to
quality as we expand our medical service offering to home sleep
testing in the first quarter of 2010.

The Joint Commission on Accreditation of Healthcare Organizations
evaluates and accredits nearly 17,000 health care organizations and
programs in the United States. As an independent, not-for-profit
organization, the Joint Commission is the nation´s predominant
standards-setting and accrediting body in health care.

"This additional accreditation further demonstrates LifeWatch´s
commitment to provide patients with the highest quality clinical
services in the industry," stated Dr. Yacov Geva, Chairman and Chief
Executive Officer of LifeWatch AG.

NiteWatch provides Home Sleep Testing for diagnosing Obstructive
Sleep Apnea (OSA), a widely undiagnosed medical condition that is
highly correlated with other chronic diseases. Thirty eight million
Americans are affected by OSA, of which fifteen million are
undiagnosed. The U.S. market for OSA is currently estimated at USD
1.5 billion, out of which an estimated one million tests are
conducted annually. This market is projected to grow between 20-50%
in the next five years, with home sleep testing capturing
approximately 20% of the total market. LifeWatch, as the first
Cardiac IDTF to enter into home sleep testing services, will leverage
its medical monitoring expertise into a competitive advantage, and
diversify LifeWatch´s service offering. LifeWatch is fully on track
with its planned roll out of the NiteWatch service and has expanded
its beta launch to 12 clients and is now approaching 50 patients. The
Company has already signed 166 commercial managed care contracts
covering 90 million lives for its new NiteWatch service and will
continue to broaden coverage with additional contracts.

About LifeWatch AG

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless remote patient monitoring services. LifeWatch
services treat high-risk and chronically ill patients, health
conscious consumers and wellness programs. LifeWatch has subsidiaries
in the United States, the Netherlands, Japan, the United Kingdom,
Switzerland and Israel. LifeWatch AG is the parent company of
LifeWatch Services Inc., a leading US-based cardiac monitoring
service provider, and manufacturer of telecardiology products.
LifeWatch is also introducing a new program for Home Sleet Testing of
Obstructive Sleep Apnea (OSA) patients under the brand name
NiteWatch. For additional information, please visit www.lifewatch.com
and www.nitewatchservices.com

Sign-up for customized e-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. LifeWatch AG has based these forward
looking statements largely on current expectations and projections
about future events and financial trends that it believes may affect
the financial condition, results of operations, business strategy,
short term and long term business operations and objectives, and
financial needs. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions. In light of these
risks, uncertainties and assumptions, the forward-looking events and
circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based
only on data available to LifeWatch AG at the time of the issue of
this press release. LifeWatch AG does not undertake any obligation to
update any forward- looking statements contained in this press
release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: LifeWatch AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Kobi Ben Efraim, Chief Financial Officer, LifeWatch AG:

Tel +41 52 632 00 50 | Fax +41 52 632 00 51 | E-mail kobibe@lifewatch.com

Sensus Investor & Public Relations GmbH, Zürich:

Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail lifewatch@sensus.ch

Branche: Healthcare Providers
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / free trade